Opin vísindi
→
Browsing by Author

Browsing by Author "Guðbjörnsson, Björn"

Now showing items 1-10 of 10

Aldarafmæli D-vítamíns

Guðbjörnsson, Björn (2022-07-07)
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration

Lindström, Ulf; Di Giuseppe, Daniela; Delcoigne, Bénédicte; Glintborg, Bente; Möller, Burkhard; Ciurea, Adrian; Pombo-Suarez, Manuel; Sanchez-Piedra, Carlos; Eklund, Kari; Relas, Heikki; Guðbjörnsson, Björn; Löve, Þorvarður Jón; Jones, Gareth T.; Codreanu, Catalin; Ionescu, Ruxandra; Nekvindova, Lucie; Závada, Jakub; Atas, Nuh; Yolbas, Servet; Fagerli, Karen Minde; Michelsen, Brigitte; Rotar, Ziga; Tomšič, Matija; Iannone, Florenzo; Santos, Maria Jose; Avila-Ribeiro, Pedro; Ørnbjerg, Lykke Midtbøll; Østergaard, Mikkel; Jacobsson, Lennart T.H.; Askling, Johan; Nissen, Michael J. (2021-06-03)

Background Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains ...
Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis : a collaborative observational study across five Nordic rheumatology registers

Delcoigne, Benedicte; Kopp, Tine Iskov; Arkema, Elizabeth V.; Hellgren, Karin; Provan, Sella Aarrestad; Relas, Heikki; Aaltonen, Kalle; Trokovic, Nina; Guðbjörnsson, Björn; Gröndal, Gerður María; Klami Kristianslund, Eirik; Lindhardsen, Jesper; Dreyer, Lene; Askling, Johan (2023-02-28)

Objective To compare incidences of neuroinflammatory events, including demyelinating disease (DML), inflammatory polyneuropathies (IPN) and multiple sclerosis (MS), in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA; including psoriatic ...
Is the risk of infection higher during treatment with secukinumab than with TNF-inhibitors? : An observational study from the Nordic countries

Glintborg, Bente; Di Giuseppe, Daniela; Wallman, Johan K; Provan, Sella A; Nordström, Dan; Hokkanen, Anna-Mari; Österlund, Jenny; Kristianslund, Eirik; Kvien, Tore K; Guðbjörnsson, Björn; Hetland, Merete Lund; Michelsen, Brigitte; Jacobsson, Lennart; Askling, Johan; Lindström, Ulf (2022-06-20)

OBJECTIVES: The positioning of secukinumab in the treatment of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) is debated, partly due to a limited understanding of the comparative safety of available treatments. We aimed to assess risk ...
A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program

Karlsdóttir, Kristín; Gunnarsdóttir, Anna Ingibjörg; Gröndal, Gerður María; Löve, Þorvarður Jón; Stefánsdóttir, Elínborg; Davíðsdóttir, Lóa Guðrún; Thorleifsdottir, Ragna H.; Guðbjörnsson, Björn (2022-01-27)

Objective: Due to a tender process in Iceland, all patients on Humira® were switched nationwide to its biosimilar Imraldi® in March 2019. The study aimed to explore the patient's perspective of the Humira® and Imraldi® injection devices. Methods: A ...
Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial

Stockfelt, Marit; Lundell, Anna Carin; Hetland, Merete Lund; Østergaard, Mikkel; Uhlig, Till; Heiberg, Marte Schrumpf; Haavardsholm, Espen A.; Nurmohamed, Michael T.; Lampa, Jon; Nordström, Dan; Petersen, Kim Hørslev; Guðbjörnsson, Björn; Gröndal, Gerður; Aldridge, Jonathan; Andersson, Kerstin; Blennow, Kaj; Zetterberg, Henrik; van Vollenhoven, Ronald; Rudin, Anna (2021-07-13)

Background: The type I interferon (IFN) gene signature is present in a subgroup of patients with early rheumatoid arthritis (RA). Protein levels of IFNα have not been measured in RA and it is unknown whether they associate with clinical characteristics ...
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration

Ørnbjerg, Lykke Midtbøll; Linde, Louise; Georgiadis, Stylianos; Horskjær Rasmussen, Simon; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Di Giuseppe, Daniela; Wallman, Johan K.; Pavelka, Karel; Závada, Jakub; Nissen, Michael J; Jones, Gareth T.; Relas, Heikki; Pirilä, Laura; Tomšič, Matija; Rotar, Ziga; Geirsson, Árni Jón; Guðbjörnsson, Björn; Kristianslund, Eirik K.; van sder Horst-Bruinsma, Irene; Loft, Anne Gitte; Laas, Karin; Iannone, Florenzo; Corrado, Addolorata; Ciurea, Adrian; Santos, Maria José; Santos, Helena; Codreanu, Catalin; Akkoc, Nurullah; Gunduz, Ozgul S.; Glintborg, Bente; Østergaard, Mikkel; Lund Hetland, Merete (2022-10-01)

Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive ...
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

Michelsen, Brigitte; Georgiadis, Stylianos; Di Giuseppe, Daniela; Loft, Anne G.; Nissen, Michael J.; Iannone, Florenzo; Pombo-Suarez, Manuel; Mann, Herman; Rotar, Ziga; Eklund, Kari K.; Kvien, Tore K.; Santos, Maria J.; Guðbjörnsson, Björn; Codreanu, Catalin; Yilmaz, Sema; Wallman, Johan K.; Brahe, Cecilie H.; Möller, Burkhard; Favalli, Ennio G.; Sánchez-Piedra, Carlos; Nekvindova, Lucie; Tomsic, Matija; Trokovic, Nina; Kristianslund, Eirik K.; Santos, Helena; Löve, Þorvarður Jón; Ionescu, Ruxandra; Pehlivan, Yavuz; Jones, Gareth T.; van der Horst-Bruinsma, Irene; Ørnbjerg, Lykke M.; Østergaard, Mikkel; Hetland, Merete L. (2022-04-29)

Objective: There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the ...
Risaæðafrumubólga – sjúkratilfelli með drep í hársverði og skyndiblindu.

Guðbjörnsson, Björn; Árnadóttir, Berglind; Gröndal, Gerður María; Tryggvason, Þórður (2021-12)

Sumarið 2020 leitaði kona á níræðisaldri til læknis vegna höfuðverks og sjóntruflana. Greining var óljós og einkenni versnuðu hratt. Hún varð blind á báðum augum og fékk stórt drep í hársvörðinn. Um var að ræða hröð versnandi einkenni risafrumuæðabólgu ...
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs : results from four Nordic countries

Delcoigne, Benedicte; Ljung, Lotta; Provan, Sella A; Glintborg, Bente; Hetland, Merete Lund; Grøn, Kathrine Lederballe; Peltomaa, Ritva; Relas, Heikki; Turesson, Carl; Guðbjörnsson, Björn; Michelsen, Brigitte; Askling, Johan (2022-03-22)

OBJECTIVES: To compare the 1-year, 2-year and 5-year incidences of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) starting any of the biologic disease-modifying antirheumatic drugs (bDMARDs) currently available in clinical ...

Now showing items 1-10 of 10

Search Opin vísindi

Browse

All of Opin vísindi
- Communities & Collections
- Authors
- Titles
- Subjects
- Departments
- School
- DOI
- Journal title

Browsing by Author "Guðbjörnsson, Björn"

Browsing by Author "Guðbjörnsson, Björn"

Search Opin vísindi

Browse

All of Opin vísindi

About

My Account